Parkinsons

Annovis stock jumps on data for Parkinson’s drug (NYSE:ANVS)

Hailshadow/iStock via Getty Images Shares of Annovis Bio (NYSE:ANVS) more than doubled in value on Tuesday after the company said its lead asset, buntanetap, was found to be safe and effective in improving the physical and cognitive functions of patients with early Parkinson’s disease. Updating data from its Phase 3Continue Reading

FDA snubs AbbVie Parkinson’s combo (NYSE:ABBV)

In: Finance

AbbVie’s (NYSE:ABBV) new drug application for its Parkinson’s disease combination therapy has been denied approval by the FDA. In a complete response letter sent to the drugmaker, the U.S. drug regulator cited observations that were identified during inspection of a third-party manufacturer listed in the application. The inspection at theContinue Reading

Parkinsons

Annovis stock jumps on data for Parkinson’s drug (NYSE:ANVS)

FDA snubs AbbVie Parkinson’s combo (NYSE:ABBV)

Centralize model governance with SageMaker Model Registry Resource Access Manager sharing | Amazon Web Services

Revolutionize trip planning with Amazon Bedrock and Amazon Location Service | Amazon Web Services